<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649272</url>
  </required_header>
  <id_info>
    <org_study_id>OXYB-05129</org_study_id>
    <nct_id>NCT00649272</nct_id>
  </id_info>
  <brief_title>Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg</brief_title>
  <official_title>Single-Dose Fasting Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (15 mg; Mylan)and Ditropan XL® Tablets (15 mg; ALZA) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Oxybutynin Chloride&#xD;
      Extended-Release Tablets, 15 mg (Mylan Pharmaceuticals Inc.) to Ditropan XL® Extended-&#xD;
      Release Tablets, 15 mg (ALZA Corporation; Distributed and marketed by: Ortho-McNeil&#xD;
      Pharmaceuticals Inc.) following a single, oral 15 mg dose (1 x 15 mg tablet) under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxybutynin Chloride Extended-Release Tablets, 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ditropan XL® Extended-release tablets, 15 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin Chloride Extended-Release Tablets, 15 mg</intervention_name>
    <description>15mg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ditropan XL® Extended-release tablets, 15 mg</intervention_name>
    <description>15mg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 years and older.&#xD;
&#xD;
          2. Sex: Male and/or non-pregnant, non-lactating female.&#xD;
&#xD;
               1. Women of childbearing potential must have a negative serum beta human chorionic&#xD;
                  gonadotropin (β-HCG) pregnancy test performed within 28 days prior to the start&#xD;
                  of the study and on the evening prior to each dose administration. If dosing is&#xD;
                  scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48&#xD;
                  hours prior to dosing for each study period. An additional serum (β-HCG)&#xD;
                  pregnancy test will be performed upon completion of the study.&#xD;
&#xD;
               2. Women of childbearing potential must practice abstinence or be using an&#xD;
                  acceptable form of contraception throughout the duration of the study. No&#xD;
                  hormonal contraceptives or hormonal replacement therapies are permitted in this&#xD;
                  study. Acceptable forms of contraception include the following:&#xD;
&#xD;
                    1. intrauterine device in place for at least 3 months prior to the start of the&#xD;
                       study and remaining in place during the study period, or&#xD;
&#xD;
                    2. barrier methods containing or used in conjunction with a spermicidal agent,&#xD;
                       or&#xD;
&#xD;
                    3. surgical sterilization&#xD;
&#xD;
               3. Women will not be considered of childbearing potential if one of the following is&#xD;
                  reported and documented on the medical history:&#xD;
&#xD;
                    1. postmenopausal with an absence of menses for at least one (1) year, or&#xD;
&#xD;
                    2. bilateral oophorectomy with or without a hysterectomy and an absence of&#xD;
                       bleeding for at least 6 months, or&#xD;
&#xD;
                    3. total hysterectomy&#xD;
&#xD;
               4. During the course of the study, from study screen until study exit - including&#xD;
                  the washout period, all men and women of childbearing potential must use a&#xD;
                  spermicide containing barrier method of contraception in addition to their&#xD;
                  current contraceptive method. This advice should be documented in the informed&#xD;
                  consent form.&#xD;
&#xD;
          3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women with all&#xD;
             subjects having a Body Mass Index (BMI) less than or equal to 30 but greater than or&#xD;
             equal to 19. (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
          4. All subjects should be judged normal and healthy during a pre-study medical evaluation&#xD;
             (physical examination, laboratory evaluation, Hepatitis B and Hepatitis C tests, HIV&#xD;
             test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates,&#xD;
             benzodiazepines, cannabinoid, cocaine, opiates, phencyclidine, and methadone)&#xD;
             performed within 28 days of the initial dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Institutionalized subjects will not be used.&#xD;
&#xD;
          2. Social Habits:&#xD;
&#xD;
               1. Use of any tobacco-containing products within 1 year of the start of the study.&#xD;
&#xD;
               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage&#xD;
                  within the 48 hours prior to the initial dose of study medication.&#xD;
&#xD;
               3. Ingestion of any vitamins or herbal products within 7 days prior to the initial&#xD;
                  dose of the study medication.&#xD;
&#xD;
               4. Any recent, significant change in dietary or exercise habits.&#xD;
&#xD;
               5. A positive test for any drug included in the urine drug screen.&#xD;
&#xD;
               6. History of drug and/or alcohol abuse.&#xD;
&#xD;
          3. Medications:&#xD;
&#xD;
               1. Use of any prescription or over-the-counter (OTC) medications within the 14 days&#xD;
                  prior to the initial dose of study medication.&#xD;
&#xD;
               2. Use of any hormonal contraceptives or hormone replacement therapy within 3 months&#xD;
                  prior to study medication dosing.&#xD;
&#xD;
               3. Use of any medication known to alter hepatic enzyme activity within 28 days prior&#xD;
                  to the initial dose of study medication.&#xD;
&#xD;
          4. Diseases:&#xD;
&#xD;
               1. History of any significant cardiovascular, hepatic, renal, pulmonary,&#xD;
                  hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or&#xD;
                  neurologic disease.&#xD;
&#xD;
               2. Acute illness at the time of either the pre-study medical evaluation or dosing.&#xD;
&#xD;
               3. A positive HIV, hepatitis B, or hepatitis C test.&#xD;
&#xD;
               4. Risk or history of urinary retention, gastric retention or narrow angle glaucoma.&#xD;
&#xD;
          5. Abnormal and clinically significant laboratory test results:&#xD;
&#xD;
               1. Clinically significant deviation from the Guide to Clinically Relevant&#xD;
                  Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
               2. Abnormal and clinically relevant ECG tracing.&#xD;
&#xD;
          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 mL) within 28 days&#xD;
             prior to the initial dose of study medication.&#xD;
&#xD;
          7. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          8. Allergy or hypersensitivity to oxybutynin chloride or any other anticholinergics.&#xD;
&#xD;
          9. History of difficulties in swallowing, or any gastrointestinal disease which could&#xD;
             affect the drug absorption.&#xD;
&#xD;
         10. Consumption of grapefruit or grapefruit containing products within 7 days of drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan K Copa, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute Ltd. - Cetero Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute Ltd. - Cetero Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullvan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

